Mithra Launches a Research Programme on Estetrol’s Effect in Covid-19 Treatment

  • Women are more likely than men to be spared by Covid-19, with less severe infections and lower mortality rates
  • Protective role of estrogen against human coronaviruses already demonstrated during the SARS infection, and currently being tested in the U.S. among hospitalized patients
  • Mithra plans to develop a research program to study Estetrol (E4) mechanism of action in the treatment of Covid-19.

Liège, Belgium, 25 May 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its intention to launch a Phase II study program to assess the potential beneficial effect of Estetrol (E4) on Covid-19 infection. E4 is a naturally occurring estrogen produced by the liver of the human fetus, passing in maternal blood at relatively high levels during pregnancy.